AnaptysBio (ANAB) Stock: Buy, Sell, or Hold?
ANAB - AnaptysBio, Inc. Common Stock
$53.87
-1.29 (-2.34%)
âŧ
5d:
-6.25%
30d:
-5.46%
90d:
-0.68%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Sep 09, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 4, 2026 at $56.80 · last confirmed Sep 8, 2026
Strength: 3.3/10
Get Alerted When ANAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ANAB is fairly priced but lacks strong directional signals. At -2.9% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ANAB is fairly priced but lacks strong directional signals. At -2.9% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$82.16
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$51.02
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ANAB is currently trading at $53.87, which is considered fair relative to its 30-day fair value range of $55.21 to $58.42. The stock's valuation (Forward PE: 10.3) is in line with its historical norms (11.2). Remarkably, the market is currently pricing in an annual earnings decline of 2.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ANAB is in a downtrend. The price is currently testing key support at $53.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $89.62 (+66.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ANAB is in a downtrend. The price is currently testing key support at $53.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $89.62 (+66.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$55.21 -
$58.42
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 66.4% below Wall St target ($89.62)
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$55.21 -
$58.42
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$53.75
Resistance Level
$58.77
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.29
Wall Street Target
$89.63
(+66.4%)
Revenue Growth (YoY)
-8.0%
Profit Margin
-11.5%
Valuation Discount vs History
-2.9% cheaper
PE vs Historical
10.3 vs 11.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.9%
(market-implied from PE analysis)
1-Year Target
$52.31
(-3%)
2-Year Target
$50.79
(-6%)
3-Year Target
$49.32
(-9%)
3-Yr Target (if PE normalizes)
(PE: 10â11)
$53.68
(0%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.3 to 11.2
Stabilization Target:
$58.64
(+8.9%)
PE Expansion Potential:
+8.9%
Share & Embed Analysis
Last updated: September 12, 2026 3:10 PM ET
Data refreshes hourly during market hours. Next update: 4:10 PM
Data refreshes hourly during market hours. Next update: 4:10 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
John P Schmid
SELL
20645 shares
2026-03-30
Daniel Faga
SELL
17679 shares
2026-03-27
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |